[go: up one dir, main page]

MA34765B1 - Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci - Google Patents

Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci

Info

Publication number
MA34765B1
MA34765B1 MA36060A MA36060A MA34765B1 MA 34765 B1 MA34765 B1 MA 34765B1 MA 36060 A MA36060 A MA 36060A MA 36060 A MA36060 A MA 36060A MA 34765 B1 MA34765 B1 MA 34765B1
Authority
MA
Morocco
Prior art keywords
acid receptor
receptor antagonists
compounds
lysophosphatide acid
relates
Prior art date
Application number
MA36060A
Other languages
English (en)
Inventor
Thomas Jon Seiders
Bowei Wang
John Howard Hutchinson
Nicholas Simon Stock
Deborah Volkots
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34765(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of MA34765B1 publication Critical patent/MA34765B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
    • C07D231/32—Oxygen atoms
    • C07D231/36—Oxygen atoms with hydrocarbon radicals, substituted by hetero atoms, attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés antagonistes du(des) récepteur(s) de l'acide lysophosphatidique. L'invention concerne également des compositions pharmaceutiques et des médicaments comprenant les composés décrits ici, ainsi que des procédés d'utilisation de tels antagonistes, seuls ou en association avec d'autres composés, dans le but de traiter des états pathologiques ou des maladies dépendantes de l'acide lysophosphatidique ou induites par celui-ci.
MA36060A 2010-12-07 2013-06-28 Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci MA34765B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42071610P 2010-12-07 2010-12-07
PCT/US2011/063465 WO2012078593A2 (fr) 2010-12-07 2011-12-06 Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA34765B1 true MA34765B1 (fr) 2013-12-03

Family

ID=45418800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36060A MA34765B1 (fr) 2010-12-07 2013-06-28 Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci

Country Status (19)

Country Link
US (1) US9272990B2 (fr)
EP (1) EP2648714B1 (fr)
JP (1) JP2014508111A (fr)
KR (1) KR20130126659A (fr)
CN (1) CN103347510B (fr)
AU (1) AU2011338561A1 (fr)
BR (1) BR112013014019A2 (fr)
CA (1) CA2820817A1 (fr)
CL (1) CL2013001655A1 (fr)
CO (1) CO6771417A2 (fr)
EA (1) EA201390821A1 (fr)
IL (1) IL226491A0 (fr)
MA (1) MA34765B1 (fr)
MX (1) MX2013006040A (fr)
PE (1) PE20140879A1 (fr)
PH (1) PH12013501136A1 (fr)
SG (1) SG190417A1 (fr)
WO (1) WO2012078593A2 (fr)
ZA (1) ZA201304159B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975235B2 (en) * 2011-03-20 2015-03-10 Intermune, Inc. Lysophosphatidic acid receptor antagonists
MX2014014711A (es) * 2012-06-20 2015-03-04 Hoffmann La Roche Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar).
MA37765A1 (fr) * 2012-06-20 2017-04-28 Hoffmann La Roche Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA37764A1 (fr) * 2012-06-20 2016-01-29 Hoffmann La Roche Composés n-alkyltriazole utilisés comme antagonistes de lpar
JP2015524385A (ja) 2012-07-02 2015-08-24 フィブロスタティン，エス．エル． Ｇｐｂｐ−１阻害およびその治療的使用
WO2014037303A1 (fr) * 2012-09-05 2014-03-13 F. Hoffmann-La Roche Ag Composés de cyanopyrazole substitués antagonistes des lpar
BR112015007578B1 (pt) 2012-10-02 2020-05-05 Bayer Cropscience Ag Uso não terapêutico de compostos, compostos, composições emétodo não terapêutico para controlar pragas compreendendoos referidos compostos
DK2940013T3 (en) 2012-12-28 2018-03-26 Ube Industries HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
US20140213538A1 (en) * 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
EP2961746B1 (fr) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
JP2014231508A (ja) * 2013-05-02 2014-12-11 宇部興産株式会社 ハロゲン置換へテロ環化合物
EA038294B1 (ru) * 2013-05-24 2021-08-05 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
AU2015281021B9 (en) * 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
WO2016046782A1 (fr) * 2014-09-26 2016-03-31 Glenmark Pharmaceuticals S.A. Composés imidazole biaryle en tant qu'inhibiteurs de la s-nitrosoglutathion réductase
CA2988306A1 (fr) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles pour le traitement de maladies liees a la demyelinisation
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018106643A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Azoles hétérocycliques pour le traitement de maladies de démyélinisation
WO2018106641A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles pour le traitement de maladies démyélinisantes
WO2018106646A1 (fr) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles pour traiter des maladies démyélinisantes
WO2019041340A1 (fr) * 2017-09-04 2019-03-07 Eli Lilly And Company Composés inhibiteurs du récepteur 1 de l'acide lysophosphatidique (lpar1)
EP3728210A1 (fr) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison n isoxazole utilisés en tant qu'antagonistes de lpa
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
WO2019126087A1 (fr) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Acide cyclohexyle isoxazole azoles en tant qu'antagonistes de lpa
KR102698386B1 (ko) 2017-12-19 2024-08-22 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산
KR102725744B1 (ko) * 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
EP3728223B1 (fr) 2017-12-19 2022-12-28 Bristol-Myers Squibb Company Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
AU2018392325A1 (en) 2017-12-19 2020-07-30 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as LPA antagonists
EP3728196B1 (fr) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Acides carbamoyle cyclohexyliques à liaison o pyrazole utilisés en tant qu'antagonistes de lpa
ES2941774T3 (es) 2018-09-18 2023-05-25 Bristol Myers Squibb Co Acidos oxabiciclo como antagonistas de LPA
US12209072B2 (en) 2018-09-18 2025-01-28 Bristol-Myers Squibb Company Cyclopentyl acids as LPA antagonists
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112574201B (zh) * 2019-09-29 2024-04-19 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
CA3158743A1 (fr) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Pyridylsulfonamides de carbamate de triazole utilisees en tant qu'antagonistes du recepteur de lpa et leurs utilisations
US20230014137A1 (en) * 2019-11-29 2023-01-19 Ono Pharmaceutical Co., Ltd. Compound having lysophosphatidic acid receptor agonist activity and pharmaceutical use thereof
CA3157600A1 (fr) 2019-12-12 2021-06-17 Chiesi Farmaceutici S.P.A. Derives de quinazoline utilises en tant qu'inhibiteurs du recepteur 2 de lpa
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2022006470A1 (fr) 2020-07-01 2022-01-06 Vanderbilt University Méthodes de traitement d'une maladie rénale
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
EP4337641A1 (fr) 2021-05-11 2024-03-20 Gilead Sciences, Inc. Antagonistes du récepteur lpa et leurs utilisations
US12503454B2 (en) 2021-05-13 2025-12-23 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240115978A (ko) 2021-12-08 2024-07-26 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS60239743A (ja) * 1984-05-15 1985-11-28 Canon Inc 記録媒体
JPS6137885A (ja) * 1984-07-31 1986-02-22 Canon Inc Ｅｌ素子
DE3684446D1 (de) 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
EP0730019A4 (fr) * 1994-07-15 1996-12-18 Seiko Epson Corp Composition de cristaux liquides et element d'affichage a cristaux liquides produit a partir de celle-ci
GB9523946D0 (en) 1995-11-23 1996-01-24 Bayer Ag Leukotriene antagonistic benzoic acid derivatives
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
DE19907904A1 (de) * 1999-02-24 2000-08-31 Clariant Gmbh Verfahren zur Herstellung von [1,1':4',1"]-Terphenylverbindungen
JP4396808B2 (ja) 2001-02-08 2010-01-13 小野薬品工業株式会社 Ｌｐａ受容体調節剤からなる泌尿器疾患治療剤
DE60226357T2 (de) * 2001-02-08 2009-05-28 Seimi Chemical Co. Ltd., Chigasaki Flüssigkristallzusammensetzung enthaltend optisch aktive Verbindungen, und flüssig-kristallines elektrooptisches Element
AU2002305450A1 (en) 2001-05-08 2002-11-18 Yale University Proteomimetic compounds and methods
MXPA05012459A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresoras.
US20050245543A1 (en) 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
JP2009504575A (ja) 2005-08-11 2009-02-05 メルク フロスト カナダ リミテツド 新規の置換された１，２，３，−トリアゾリルメチル−ベンゾチオフェン又は−インドール並びにロイコトリエン生合成阻害剤としてのそれらの使用
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
JP5092236B2 (ja) * 2005-12-20 2012-12-05 旭硝子株式会社 重合性液晶性組成物、高分子液晶、光学素子、及びターフェニル誘導体
WO2007077844A1 (fr) * 2006-01-06 2007-07-12 Chisso Corporation Compose terphenyle monofluore ayant un groupe alcenyle, composition de cristaux liquides et ecran a cristaux liquides
MX2008009475A (es) 2006-01-23 2008-10-20 Amira Pharmaceuticals Inc Inhibidores triciclicos de 5-lipoxigenasa.
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
JP5399745B2 (ja) * 2009-03-12 2014-01-29 Ｊｘ日鉱日石エネルギー株式会社 多孔性金属錯体、多孔性金属錯体の製造方法及びガス貯蔵方法
EP2462128B1 (fr) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2011159550A2 (fr) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Antagoniste du récepteur de l'acide lysophosphatidique et ses utilisations
WO2011159633A1 (fr) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Formulations inhalables d'antagonistes de récepteur d'acide lysophosphatidique
EA024967B1 (ru) 2010-12-07 2016-11-30 Амира Фармасьютикалс, Инк. Полициклический lpaантагонист и его применение

Also Published As

Publication number Publication date
AU2011338561A1 (en) 2013-07-25
US20130253004A1 (en) 2013-09-26
SG190417A1 (en) 2013-07-31
CN103347510A (zh) 2013-10-09
JP2014508111A (ja) 2014-04-03
PE20140879A1 (es) 2014-08-06
EA201390821A1 (ru) 2013-10-30
CN103347510B (zh) 2015-11-25
US9272990B2 (en) 2016-03-01
KR20130126659A (ko) 2013-11-20
EP2648714A2 (fr) 2013-10-16
BR112013014019A2 (pt) 2016-09-13
IL226491A0 (en) 2013-07-31
CO6771417A2 (es) 2013-10-15
EP2648714B1 (fr) 2015-11-18
ZA201304159B (en) 2014-12-23
PH12013501136A1 (en) 2013-07-08
MX2013006040A (es) 2013-08-26
CL2013001655A1 (es) 2014-04-04
WO2012078593A3 (fr) 2012-08-02
CA2820817A1 (fr) 2012-06-14
WO2012078593A2 (fr) 2012-06-14

Similar Documents

Publication Publication Date Title
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA33299B1 (fr) Nouvelle formulation de naproxène
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MA39033A1 (fr) Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations
BR112014026703A2 (pt) inibidores de dna-pk
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA33296B1 (fr) Nouvelle formulation d'indométhacine
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA33295B1 (fr) Nouvelle formulation de diclofénac
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA35443B1 (fr) Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c
MA35187B1 (fr) Composés ayant une activité antagoniste d'un récepteur muscarinique et agoniste d'un récepteur béta2 adrénergique
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3